Nebulized Colistin And Continuous Cyclic Azithromycin In Severe COPD Patients With Chronic Bronchial Infection Due To Pseudomonas aeruginosa: A Retrospective Cohort Study

References

• Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359(22):2355–2365. doi:10.1056/NEJMoa080193619038881
   PubMed Web of Science ®Google Scholar
• Moreno A, Montón C, Belmonte Y, Gallego M, Pomares X, Real J. Causas de muerte en pacientes con EPOC grave. Factores pronósticos. Arch Bronconeumol. 2009;45(4):181–186. doi:10.1016/j.arbres.2008.09.00419328612
   PubMed Web of Science ®Google Scholar
• Murphy TF. Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2009;15(2):138–142. doi:10.1097/MCP.0b013e328321861a19532029
   PubMed Web of Science ®Google Scholar
• Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest. 1998;113(6):1542–1548. doi:10.1378/chest.113.6.15429631791
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Espinosa C, Fernández-Laso E, Martos JA, Maldonado JA, Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest. 1999;116(1):40–46. doi:10.1378/chest.116.1.4010424501
   PubMed Web of Science ®Google Scholar
• Gallego M, Pomares X, Espasa M, et al. Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. BMC Pulm Med. 2014;14(1):103. doi:10.1186/1471-2466-14-10324964956
   PubMed Web of Science ®Google Scholar
• Almagro P, Salvadó M, Garcia-Vidal C, et al. Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease. Respiration. 2012;84(1):36–43. doi:10.1159/00033122421996555
   PubMed Web of Science ®Google Scholar
• Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749–1756. doi:10.1001/jama.290.13.174914519709
   PubMed Web of Science ®Google Scholar
• Vendrell M, de Gracia J, Olveira C, et al. Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery. Arch Bronconeumol. 2008;44(11):629–640.19007570
   PubMed Web of Science ®Google Scholar
• Martínez-García MÁ, Máiz L, Olveira C, et al. Normativa sobre el tratamiento de las bronquiectasias en el adulto. Arch Bronconeumol. 2018;54(2):88–98.29128129
   PubMed Web of Science ®Google Scholar
• Polverino E, Goeminne PC, McDonnell MJ, et al. European respiratory society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629. doi:10.1183/13993003.00711-201728889110
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease; 2019 Available from: www.goldcopd.org. Accessed March 1, 2019.
   Google Scholar
• Dal Negro R, Micheletto C, Tognella S, Visconti M, Turati C. Tobramycin Nebulizer Solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation. Adv Ther. 2008;25(10):1019–1030. doi:10.1007/s12325-008-0105-218821068
   PubMed Web of Science ®Google Scholar
• Bruguera-Avila N, Marín A, Garcia-Olive I, et al. Effectiveness of treatment with nebulized colistin in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2909–2915. doi:10.2147/COPD.S15088729042767
   PubMed Web of Science ®Google Scholar
• Steinfort DP, Steinfort C. Effect of long-term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J. 2007;37(7):495–498. doi:10.1111/j.1445-5994.2007.01404.x17547727
   PubMed Web of Science ®Google Scholar
• Pomares Amigó X, Montón Soler C. Respiratory day hospital: what have we learned? Med Clin (Barc). 2011;136(10):454–455. doi:10.1016/j.medcli.2009.07.02819819498
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish COPD guidelines (GesEPOC): pharmacological treatment of stable COPD. Aten Primaria. 2012;44(7):425–437. doi:10.1016/j.aprim.2012.04.00522704760
   PubMed Web of Science ®Google Scholar
• Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(5Suppl 2):398S–401S. doi:10.1378/chest.117.5_suppl_2.398S10843984
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196–204. doi:10.7326/0003-4819-106-2-1963492164
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi:10.1164/rccm.201701-0150WS28128970
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. Wayne (PA): Clinical and Laboratory Standards Institute; 2010.
   Google Scholar
• Magiorakos A-P, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x21793988
   PubMed Web of Science ®Google Scholar
• Aliberti S, Chalmers JD, Pletz MW, editors. Anti-Infectives and the Lung. Vol. 75 European Respiratory Society;2017.
   Google Scholar
• Pomares X, Montón C, Espasa M, Casabon J, Monsó E, Gallego M. Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations. Int J Chron Obstruct Pulmon Dis. 2011;6:449–456. doi:10.2147/COPD.S2365522003290
   PubMed Web of Science ®Google Scholar
• Pomares X, Montón C, Bullich M, et al. Clinical and safety outcomes of long-term azithromycin therapy in severe COPD beyond the first year of treatment. Chest. 2018;153(5):1125–1133. doi:10.1016/j.chest.2018.01.04429427576
   PubMed Web of Science ®Google Scholar